Leadership Changes - Pediatrix Medical Group, Inc. appointed Mr. Mark S. Ordan as the new Chief Executive Officer, succeeding Dr. James D. Swift[5] Financial Performance - The company provided an update on its expected adjusted EBITDA for the fiscal year ended December 31, 2024[5]

Physician services provider Pediatrix Medical Group, Inc. (MD) is set to report its fourth-quarter 2024 results on Feb. 20, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 37 cents per share and $485.68 million, respectively.See the Zacks Earnings Calendar to stay ahead of market-making news.The earnings estimate for the to-be-reported quarter has remained stable over the past 60 days. The bottom-line projection indicates a year ...

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) announces that it has granted incentive stock options to employees, directors and officers of Midland to acquire an aggregate of 800,000 common shares at $0.33 per share, for a period of 10 years. These incentive stock options have been granted in accordance with Midland’s stock option plan (the “Plan”). Considering the present grant, there is 7,060,000 stock options outstanding. Amendment to Plan On December 5, 202 ...

Figure 1 Midland Overview of its 2025 Follow-Up Exploration Activities Figure 2 Midland Overview of its 2025 Follow-Up Exploration Activities Figure 3 Midland Overview of its 2025 Follow-Up Exploration Activities Figure 4 Midland Overview of its 2025 Follow-Up Exploration Activities Figure 5 Midland Overview of its 2025 Follow-Up Exploration Activities MONTREAL, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to give an overview of its explor ...

Core Insights - The rising share of commercial births in Florida is a significant growth driver for the company, expected to support margin growth [1] - The company is restructuring its portfolio by exiting affiliated office-based practices, aiming for an annual adjusted EBITDA improvement of approximately $30 million, with some benefits realized in 2024 and the remainder in 2025 [1] - The management forecasts adjusted EBITDA for 2024 to be between $205 million and $215 million, indicating a 4.8% improvement from 2023 [2] - The company is actively pursuing inorganic growth through M&A opportunities, having acquired a maternal-fetal medicine practice for $9.7 million in Q1 [3] - Stable same-facility patient volume growth is expected to continue, along with a 5.3% increase in hospital contract administrative fees in the first nine months of 2024 [4] Financial Performance - The consensus estimate for 2024 adjusted earnings per share is $1.35, reflecting a 7.1% year-over-year growth, with revenue growth estimated at 0.1% [5] - The stock is currently trading at a discount, with a forward P/E ratio of 9.28X compared to the industry average of 13.98X, indicating undervaluation [8] - Over the past six months, the stock has surged 80.9%, outperforming the industry and key peers [10] Long-term Outlook - The company has strong long-term potential due to its focus on maternal-fetal medicine, stable patient volume growth, and projected EBITDA improvements from restructuring [13] - The completed transition to a hybrid RCM structure and active M&A activity further position the company for continued growth [13]

Core Insights - Midland Exploration Inc. and Rio Tinto Exploration Canada Inc. have announced the results from the 2024 drilling campaign at the Galinée project, focusing on lithium mineralization [7][8] - The drilling campaign aimed to test multiple lithium showings, including Iceberg, White Stripes, Surge, Snow Fox, and White Lightning, with a total of 28 drill holes completed [7][8] - The project is located approximately 5 kilometers east of the Adina lithium deposit, which has a mineral resource estimate of 77.8 million tonnes at 1.15% Li2O [7][8] Drilling Results - The best results from the 2024 drilling campaign include: - 1.03% Li2O over 32.87 meters (TLIB0026) - 1.46% Li2O over 27.34 meters (TLIB0018) - 1.58% Li2O over 35.05 meters (TLIB0022 RC) - 0.76% Li2O over 38.73 meters (TLIB0020) [8][12] - A total of 21 diamond drill holes and 7 reverse circulation drill holes were completed, totaling 6,284.86 meters [8][12] - At least seven spodumene pegmatite bodies were identified, which remain open for further testing [8][12] Future Plans - Drilling is planned to resume in March 2025, with a budget of USD 3.59 million allocated for further exploration [14] - Early metallurgical tests are being evaluated on select core sections to determine lithium mineralogy and grain size [14] Geological Context - The Galinée project is situated in a favorable geological setting, with a major structure likely controlling the emplacement of pegmatites [14] - The Iceberg lithium showing was discovered along a contact zone that extends over more than 7 kilometers [14] Quality Control Measures - RTEC's sampling protocols include the use of blanks, duplicates, and standards to ensure data integrity [14]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead ...

Core Viewpoint - Momentum investing focuses on buying stocks that are trending upwards, contrasting with the traditional strategy of buying low and selling high. This approach can lead to significant gains but carries risks if stocks lose momentum after becoming overvalued [1]. Group 1: Momentum Investing Strategy - Momentum investing involves buying high and selling higher, aiming for quick profits from fast-moving stocks [1]. - Identifying the right entry point for momentum stocks is challenging, as they may lose momentum if their valuations exceed future growth potential [1]. Group 2: Bargain Stocks with Momentum - A safer investment strategy is to target bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify these opportunities [2]. - The 'Fast-Paced Momentum at a Bargain' screen helps investors find fast-moving stocks that remain attractively priced [2]. Group 3: Pediatrix Medical Group (MD) Analysis - Pediatrix Medical Group (MD) has shown a four-week price change of 33.7%, indicating strong investor interest [3]. - Over the past 12 weeks, MD's stock has gained 55.7%, demonstrating its ability to deliver positive returns over a longer timeframe [4]. - MD has a beta of 1.55, suggesting it moves 55% more than the market in either direction, indicating fast-paced momentum [4]. Group 4: Valuation and Earnings Estimates - MD has a Momentum Score of B, suggesting it is an opportune time to invest in the stock [5]. - The stock has a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which typically attract more investors [6]. - MD is trading at a Price-to-Sales ratio of 0.69, indicating it is relatively cheap, as investors pay only 69 cents for each dollar of sales [6]. Group 5: Additional Investment Opportunities - Besides MD, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [7]. - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [8].

Pediatrix Medical Group, Inc. (MD) shares have jumped 30.5% since it reported strong third-quarter results on Nov. 1, 2024. The company benefited from growth in same-unit revenues and improved hospital contract administrative fees. However, the upside was partly offset by an increased expense level. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. MD reported third-quarter 2024 adjusted earnings per share (EPS) of 44 cents, which outpaced the Zacks Consensus Estimate by 18.9%. Also, ...